Verdict: Side-by-side breakdown using the Bull Rankings model. UTHR scored 55.0, NBIX scored 87.2 — NBIX leads.
Compare another set
UTHR
United Therapeutics Corporation
Drug Manufacturers - Specialty & Generic · Quality-Growth
55
$549.16 · $23.6B
fundamentals as of
Score gap
32.2
NBIX leads
NBIX
Neurocrine Biosciences, Inc.
Drug Manufacturers - Specialty & Generic · Quality-Growth
87.2
$142.44 · $14.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestUTHR19.7x
Fastest growthNBIX+34.4%
Strongest balance sheetUTHR0.00
Highest qualityUTHR94 / 100
Largest discount to fair valueNBIX-24%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
UTHR
stronger →← stronger
NBIX
94
Qualityreturns · margins · balance sheet
80
50
Growthrevenue & earnings expansion
96
35
Valuevaluation vs sector peers
86
NBIX is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
UTHR
NBIX
$1.1bC+
FCF
$870mC+
+2.5%C
Rev
+34.4%A
0.00A
D/E
0.12B+
19.7xB+
P/E
20.9xB+
2.22C
PEG
0.28A
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
UTHR
NBIX
26% above
Price vs fair valuelower is cheaper
24% below
~13%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~7%/yr
-27%
1-yr DCF upside
+5%
-21%
5-yr DCF upside
+32%
-11%
10-yr DCF upside
+85%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Drug Manufacturers - Specialty & Generic · market cap $23.6b. 10% off the 52-week high of $609.35. 14 sell-side analysts rate this a Buy with a mean 1-yr target of $651.86 (implying +19% upside).
Moat
Net margin 42% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 20% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Drug Manufacturers - Specialty & Generic · market cap $14.5b. Down 23% from 52-week high of $186.12 — deep drawdown territory. Revenue growing +34% — in hypergrowth territory. PEG 0.28 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $207.29 (implying +46% upside).
Moat
Net margin 21% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 19% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 123% of net income — earnings translate cleanly into cash.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where UTHR and NBIX diverge
On the headline score the gap is 32.2 points in favor of NBIX. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
ValueUTHR 35.4 · NBIX 86.0NBIX +50.6
GrowthUTHR 50.2 · NBIX 95.9NBIX +45.7
QualityUTHR 94.0 · NBIX 80.5UTHR +13.5
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is NBIX or UTHR the better stock?
NBIX scores higher: NBIX 87.2, UTHR 55.0 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do NBIX and UTHR differ most?
The widest gap is value, where NBIX leads by 51 points on the 0–100 pillar scale. Neither name sweeps: they trade the lead across the three pillars, so the comparison is a trade-off rather than one being better on every measure.
How are NBIX and UTHR scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.